- Home
- CRDF vs CRBU Comparison
CRDF vs CRBU Comparison
Compare CRDF & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- CRBU
- Stock Information
- Founded
- CRDF 1999
- CRBU 2011
- Country
- CRDF United States
- CRBU United States
- Employees
- CRDF N/A
- CRBU N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- CRDF Health Care
- CRBU Health Care
- Exchange
- CRDF Nasdaq
- CRBU Nasdaq
- Market Cap
- CRDF 144.4M
- CRBU 165.8M
- IPO Year
- CRDF N/A
- CRBU 2021
- Fundamental
- Price
- CRDF $2.00
- CRBU $1.88
- Analyst Decision
- CRDF Strong Buy
- CRBU Strong Buy
- Analyst Count
- CRDF 5
- CRBU 3
- Target Price
- CRDF $11.10
- CRBU $6.67
- AVG Volume (30 Days)
- CRDF 1.1M
- CRBU 718.1K
- Earning Date
- CRDF 11-06-2025
- CRBU 11-05-2025
- Dividend Yield
- CRDF N/A
- CRBU N/A
- EPS Growth
- CRDF N/A
- CRBU N/A
- EPS
- CRDF N/A
- CRBU N/A
- Revenue
- CRDF $545,000.00
- CRBU $9,121,000.00
- Revenue This Year
- CRDF N/A
- CRBU $9.23
- Revenue Next Year
- CRDF N/A
- CRBU N/A
- P/E Ratio
- CRDF N/A
- CRBU N/A
- Revenue Growth
- CRDF N/A
- CRBU N/A
- 52 Week Low
- CRDF $1.90
- CRBU $0.66
- 52 Week High
- CRDF $5.64
- CRBU $3.00
- Technical
- Relative Strength Index (RSI)
- CRDF 48.21
- CRBU 50.97
- Support Level
- CRDF N/A
- CRBU $1.78
- Resistance Level
- CRDF $2.27
- CRBU $1.92
- Average True Range (ATR)
- CRDF 0.11
- CRBU 0.12
- MACD
- CRDF -0.04
- CRBU -0.01
- Stochastic Oscillator
- CRDF 87.89
- CRBU 27.53
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.